Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADT Inc (ADT) vs Crispr Therapeutics AG (CRSP) Price & Performance

Crispr Therapeutics AGTrade

Price performance (Past 24H)

Key statistics

ADT Inc vs Crispr Therapeutics AG — how do they compare? ADT Inc trades at $7.34 (market cap $5.44B), while Crispr Therapeutics AG trades at $53.94 (market cap $5.23B). The key difference: ADT Inc and Crispr Therapeutics AG are close in size by market cap, and ADT Inc pays a 2.95% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.

ADTCRSP
Market Cap
$5.44B$5.23B
Sector
IndustrialsHealth
52-Week High
$8.85$76.78
52-Week Low
$6.30$44.34
Enterprise Value
$13.13B$3.65B
Dividend Yield
2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADT Inc

ADT trades at $7.31, down 2.66% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The company shows solid fundamentals with a P/E of 10.35, net income margin of 11.86%, and consistent revenue growth, supported by positive analyst sentiment and institutional buying.

Outlook remains positive due to strong cash flow, dividend payments, and AI integration, but risks include high debt levels and competitive pressures. Wall Street consensus leans bullish with 47% buy ratings, suggesting potential upside if execution continues.

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.

The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.

Returns comparison

Trailing returns across standard periods

About ADT Inc

ADT Inc is a provider of monitored security, interactive home and business automation, and related monitoring services in the United States and Canada. ADT offers residential, commercial, and multi-site customers a comprehensive set of burglary, video, access control, fire and smoke alarm, and medical alert solutions. It provides interactive home and business automation solutions designed to control access, react to movement, and sense carbon monoxide, flooding, changes in temperature or other environmental conditions, as well as address personal emergencies, such as injuries and medical emergencies. In addition, it offers professional monitoring of third-party devices through ADT Canopy platform. The product brands of the company are ADT and ADT Pulse, and Protection One brand.

Read more on ADT

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP